Canton Strategic Holdings Inc
CNTN
NASDAQ·Healthcare·Biotechnology·Mkt cap $175.8M
$2.28
▲ +1.33%
P/E
11.40
Mkt Cap
$175.8M
52-Wk Range
$1.75–$6.89
52-Week Range
$1.75 - $6.89
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 23.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary Canton blockchain network with institutional infrastructure focus
- Innovative buccal film drug delivery technology reducing treatment burden
- Dual-asset strategy combining fintech and biotech opportunities
- Clinical-stage assets addressing unmet medical needs with differentiated formulations
Bear Case
1 risk
- Average volatility.
Growth
Profitability at risk
Advancement of GV104 and GV023 through clinical development stages toward commercialization
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Weak
-14.0% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying CNTN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Dec 2, 2026
AUG 14, 2026
Most recent quarter reported revenue of $1.5M. Reported EPS of -$0.08. Gross margin 100.0%.
Reported EPS · last 4Q
0 of 1 beats
Q3 26
—
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$1.5M
Margins · last 8Q
Gross
100.0%
Operating
-80.4%
Profit
-1287.2%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How CNTN stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related